Spinal cord injury: time to move?

Area of Science:

• Neuroscience
• Regenerative Medicine
• Clinical Trials

Background:

• Spinal cord injury (SCI) involves primary and secondary damage, triggering processes that affect axonal reconnection.
• Endogenous mechanisms can hinder or promote axonal regrowth from supralesional structures after SCI.

Purpose of the Study:

• To summarize the scientific foundations for current and planned clinical trials in spinal cord injury (SCI) patients.
• To review emerging neurobiological and rehabilitative strategies for promoting functional recovery after SCI.

Main Methods:

• Review of animal studies on pharmacological interventions (anti-Nogo, anti-Rho) to reduce axonal growth inhibitors.
• Discussion of cell-based therapies including autologous macrophages, vaccines, and stem cell-derived oligodendrocytes.
• Integration of neurosurgical approaches and rehabilitative strategies targeting central pattern generators.

Main Results:

• Pharmacological agents can modulate repulsive barriers, aiding axonal regeneration and sprouting.
• Cell grafts show potential for enhancing immune responses and remyelination.
• Combined neurobiological and rehabilitative approaches may restore sensorimotor functions like locomotion.

Conclusions:

• Current and planned clinical trials for SCI are supported by basic and clinical neuroscience research.
• Multifaceted approaches including pharmacological, cellular, surgical, and rehabilitative strategies offer hope for significant functional recovery.
• Further research is essential across all therapeutic fronts to optimize outcomes for spinal cord injury patients.